Jennifer J. Hitchcock
650-335-7854
jhitchcock@fenwick.com
Partner
Corporate
Jennifer J.
Hitchcock
Jennifer J.
Hitchcock
Jennifer J.
Hitchcock
Partner
Corporate

Jen advises technology and life sciences clients on capital markets and general public company corporate matters. Jen represents companies and underwriters in a wide range of capital markets transactions, including initial public offerings, direct listings and follow-on offerings in equity and debt. She also represents public companies in securities law compliance and disclosure matters and corporate governance matters.

  • UserTesting initial public offering
  • Coinbase direct listing and convertible senior notes offering
  • Nurix Therapeutics initial public offering and follow-on public offering
  • Peloton initial public offering and convertible senior notes offering
  • Sutro Biopharma initial public offering
  • Cloudera initial public offering and follow-on public offering
  • Fitbit initial public offering and follow-on public offering
  • Chegg follow-on public offering and convertible senior notes offering
  • Dermira multiple follow-on public offerings and convertible senior notes offering
  • Corium International multiple follow-on public offerings
  • Veracyte follow-on public offering
  • Agilent Technologies senior notes offering
  • Cisco senior notes offering
  • AppLovin initial public offering*
  • Pivotal Software initial public offering*
  • Adaptive Biotechnologies initial public offering and follow-on public offerings*
  • Impinj initial public offering, follow-on public offering and convertible senior notes offering*
  • New Relic initial public offering*

*Representing the representatives on behalf of the underwriters/initial purchasers, including such investment banks as Goldman Sachs, Morgan Stanley, J.P. Morgan, BofA Securities, RBC Capital Markets, Allen & Company, Pacific Crest Securities, a division of KeyBanc Capital Markets, Piper Jaffray, and UBS Securities, among others.

  • UserTesting initial public offering
  • Coinbase direct listing and convertible senior notes offering
  • Nurix Therapeutics initial public offering and follow-on public offering
  • Peloton initial public offering and convertible senior notes offering
  • Sutro Biopharma initial public offering
  • Cloudera initial public offering and follow-on public offering
  • Fitbit initial public offering and follow-on public offering
  • Chegg follow-on public offering and convertible senior notes offering
  • Dermira multiple follow-on public offerings and convertible senior notes offering
  • Corium International multiple follow-on public offerings
  • Veracyte follow-on public offering
  • Agilent Technologies senior notes offering
  • Cisco senior notes offering
  • AppLovin initial public offering*
  • Pivotal Software initial public offering*
  • Adaptive Biotechnologies initial public offering and follow-on public offerings*
  • Impinj initial public offering, follow-on public offering and convertible senior notes offering*
  • New Relic initial public offering*

*Representing the representatives on behalf of the underwriters/initial purchasers, including such investment banks as Goldman Sachs, Morgan Stanley, J.P. Morgan, BofA Securities, RBC Capital Markets, Allen & Company, Pacific Crest Securities, a division of KeyBanc Capital Markets, Piper Jaffray, and UBS Securities, among others.

  • Coinbase
  • Fitbit
  • Goldman Sachs
  • JPMorgan
  • Morgan Stanley
  • Nurix Therapeutics
  • Peloton
  • UserTesting

  • Coinbase
  • Fitbit
  • Goldman Sachs
  • JPMorgan
  • Morgan Stanley
  • Nurix Therapeutics
  • Peloton
  • UserTesting

Recognition Recognition Recognition

Recognition Recognition Recognition

Recognition
Law360

2022

Named Jen a Law360 Rising Star for Capital Markets.

Recognition
Law360

2022

Named Jen a Law360 Rising Star for Capital Markets.

Login

Don’t have an account yet?

Register